Embodiments of the present invention relate generally to the treatment of wounds using negative pressure wound therapy, and more specifically to an improved apparatus and method thereof.
The treatment of open or chronic wounds that are too large to spontaneously close or otherwise fail to heal by means of applying negative pressure to the site of the wound is well known in the art. Negative pressure wound treatment systems currently known in the art commonly involve placing a cover that is impermeable to liquids over the wound, using various means to seal the cover to the tissue of the patient surrounding the wound, and connecting a source of negative pressure (such as a vacuum pump) to the cover in a manner so that an area of negative pressure is created under the cover in the area of the wound.
Embodiments of the invention disclosed herein are directed to a reduced pressure appliance and methods of treatment using a reduced pressure appliance, and may be useful in the treatment of wounds using reduced pressure.
Certain embodiments of the invention employ fluidic connectors and/or suction adapters for connecting a source of negative pressure to a dressing positioned over a wound site. These fluidic connectors and/or suction adapters offer advantages over the prior art. For example and for illustrative purposes only, some of the embodiments may offer a softer, kink-free fluidic connector for connecting a wound site to a source of negative pressure for treatment. Such a fluidic connector and/or suction adapter is faster to apply, requiring fewer steps compared to prior art connectors, and offers greater patient comfort and safety by being soft and conformable, thereby avoiding pressure ulcers and other complications caused by harder connectors.
Also disclosed herein are embodiments of an apparatus for providing suction to a wound site comprising a top and bottom layer constructed from a liquid-impermeable material with a 3D knitted or 3D fabric material located between these top and bottom layers and forming an elongate channel.
In another embodiment of a suction adapter, this adapter has an applicator with an upper and lower surface, with the upper surface connected to the distal end of a bridge. The bridge has a proximal end and a distal end, and has an upper fluid passage connected to an air leak and a lower fluid passage in fluid communication with a source of negative pressure, with the lower fluid passage comprising a 3D knitted or 3D fabric material.
In some embodiments of the suction adapter, the upper fluid passage may comprise foam. The bridge portion may further comprise a top layer, a bottom layer and an intermediate layer, each of the layers having proximal ends and distal ends and elongate portions extending therebetween, where the upper fluid passage extends between the top and intermediate layers, and the lower fluid passage extends between the intermediate and bottom layers. The distal end of the bridge may also have an enlarged shape. The air leak may be disposed at the proximal end of the bridge. The 3D knitted or 3D fabric material may include a top knitted layer, a bottom knitted layer, and a middle area with vertically extending fibers, and may be approximately 1.5 to 6 mm thick. The 3D knitted or 3D fabric material may be constructed so as to resist compression to less than half its original thickness when subjected to a load of 15 psi.
The suction adapter embodiments above may be used in embodiments of a negative pressure wound treatment system comprising a flexible drape configured to be positioned over a wound and sealed to the skin surrounding the wound, and where the suction adapter is configured to be attached to the drape so as to surround at least one aperture formed in the drape. A vacuum pump is preferably connected by at least one conduit to the suction adapter.
Methods of treating a wound with negative pressure are also disclosed herein. A method of treating a wound site with negative pressure comprises applying a flexible drape over a wound site, applying a flexible suction adapter over an opening in the flexible drape, where the flexible suction adapter comprises top and bottom layers constructed from a liquid-impermeable material, a 3D knitted or 3D fabric material located between the top and bottom layers, an aperture in the bottom layer in fluid communication with the wound site through the opening and the 3D knitted or 3D fabric material, and applying negative pressure to the wound, the negative pressure being transmitted to the wound through at least one conduit connected between the source of negative pressure and the flexible suction adapter and passing through the 3D knitted or 3D fabric material through the aperture in the bottom layer and into the opening in the flexible drape.
In some embodiments, the application of negative pressure to the wound may cause air to flow into the wound via an air leak disposed on the flexible suction adapter. The flow rate of air, may, in some embodiments be at least 0.08 liters/minute when negative pressure is applied to the suction adapter, and this flow rate may be maintained while a weight is placed on the suction adapter, for example a 4.75 kg weight. Adhesive may be placed on the suction adapter when adhering the adapter to the drape, or the adapter can be supplied pre-attached to a drape. Otherwise, the method above may comprise cutting an opening into the drape. Wound contact material can also be placed into the wound site prior to applying the drape. A similar method may transmit negative pressure to the wound through at least one conduit connected between the source of negative pressure and the flexible suction adapter and that passes through the 3D knitted material into the opening in the flexible drape.
In another embodiment, a negative pressure wound treatment system comprises a conduit, a suction adapter and a connector. The conduit is configured to deliver negative pressure to the wound from a source of negative pressure. The suction adapter is configured to deliver negative pressure to the wound, wherein the suction adapter comprises an elongate fluid channel having a proximal and a distal end and an elongate 3D knitted or 3D fabric material extending between the proximal and distal ends. A connector is configured to securely attach to a proximal portion of the 3D knitted or 3D fabric material, the connector being further configured to create a fluidic connection between the 3D knitted material in the elongate fluid channel and the conduit. In certain embodiments, the connector is configured to remain attached to the 3D knitted or 3D fabric material when subjected to a pulling force of less than 20 kg.
In some embodiments, the connector comprises two distally extending projections, each projection further comprising at least one barb located thereon, the barbs configured to be pushed into and be retained within a proximal portion of the 3D knitted or 3D fabric material. The connector may further comprise two distally extending projections, each projection further comprising at least one barb located thereon, the barbs configured to attach to upper and lower portions of the 3D knitted or 3D fabric material.
In other embodiments, the connector comprises a central distally extending projection configured to extend into the 3D knitted or 3D fabric material. The central projection may further comprise at least one barb.
In another embodiment, the connector comprises at least one opening configured to receive a pin or other locking device, and wherein the pin is pushed through at least a portion of the 3D knitted or 3D fabric material.
In another embodiment, the connector comprises a central channel and at least one lip configured to be pushed into and secured inside a proximal portion of the 3D knitted or 3D fabric material.
In another embodiment, the connector comprises at least one flexible line and one corresponding cavity configured to receive the at least one line, the line being configured to loop into a proximal portion of the 3D knitted or 3D fabric material. The line may further comprise at least one barb.
In another embodiment, a connector for connecting a fluid passage tube to a fabric channel is provided. The connector comprises a hollow cylindrical body comprising a central channel extending between a proximal end and a distal end of the hollow body. A plurality of projections extend distally from the hollow body. A plurality of barbs are provided on each of the projections, wherein the barbs are angled proximally, the barbs being configured to engage the fabric channel. A frustoconical lip at the proximal end of the hollow body is configured to be press-fit into the fluid passage tube. The connector is configured to withstand a pulling force of up to 20 kg before disengaging from the fabric channel.
In another embodiment, the connector for connecting a fluid passage tube to a fabric channel comprises a body having a proximal end and a distal end. At least one member extends distally from the body, the at least one member configured to extend into the fabric channel. The proximal end of the body is configured to be press-fit with an inner or outer surface of the fluid passage tube.
In some embodiments, the body may be cylindrical and/or hollow. The at least one member may comprise a plurality of projections, and the projections may additionally comprise one or more barbs extending in a proximal direction. The member may alternatively comprise at least one flexible line, and wherein the line comprises a tapered tip configured to loop through the fabric channel and be received and securely connected to a cavity formed in the connector. The proximal end of the body may comprise a frustoconical lip.
In another embodiment, a fluidic connection is provided, comprising any of the aforementioned connectors. A fabric channel is engaged with the proximal end of the connector. A tube is engaged with the distal end of the connector.
In another embodiment, a method of transporting fluid. The method comprises providing an elongate fluid channel comprising a 3D knitted or 3D fabric material. A connector is attached to the 3D knitted or 3D fabric material, wherein a distal end of the connector engages the 3D knitted or 3D fabric material. A conduit is attached to a proximal end of the connector. Fluid is transported through the 3D knitted or 3D fabric material, through the connector and through the conduit.
In some embodiments, the transporting of fluid comprises applying negative pressure to the conduit, the connector and the 3D knitted or 3D fabric material. The 3D knitted or 3D fabric material may be placed in fluid communication with a wound, wherein applying negative pressure comprises transmitting negative pressure through the conduit, the connector and the 3D knitted or 3D fabric material to the wound. In one embodiment, pulling on the connector with a force less than 20 kg does not dislodge the connector from the 3D knitted or 3D fabric material.
Preferred embodiments disclosed herein relate to wound therapy for a human or animal body. Therefore, any reference to a wound herein can refer to a wound on a human or animal body, and any reference to a body herein can refer to a human or animal body. The term “wound” as used herein, in addition to having its broad ordinary meaning, includes any body part of a patient that may be treated using reduced pressure. Wounds include, but are not limited to, open wounds, pressure sores, ulcers and burns. Treatment of such wounds can be performed using negative pressure wound therapy, wherein a reduced or negative pressure can be applied to the wound to facilitate and promote healing of the wound. It will also be appreciated that the negative pressure systems and methods as disclosed herein may be applied to other parts of the body, and are not necessarily limited to treatment of wounds.
With reference initially to
The application of reduced or negative pressure to a wound in the above manner may be used to promote faster healing, increase blood flow, decrease bacterial burden, increase the rate of granulation tissue formation, remove exudate and slough from the wound, alleviate interstitial edema, stimulate the proliferation of fibroblasts, stimulate the proliferation of endothelial cells, close chronic open wounds, inhibit burn penetration, and enhance flap and graft attachment, among other things. It has also been reported that wounds that have exhibited positive response to treatment by the application of negative pressure include infected open wounds, decubitus ulcers, dehisced incisions, partial thickness burns, and various lesions to which flaps or grafts have been attached.
Suitable drapes such as those used in the embodiments described herein are preferably liquid tight, such that at least partial negative pressure may be maintained at the wound site. The drape may be constructed from, for example, transparent flexible plastics such as polyurethane. Other suitable materials include without limitation synthetic polymeric materials that do not absorb aqueous fluids, including polyolefins, such as polyethylene and polypropylene, polysiloxanes, polyamides, polyesters, and other copolymers and mixtures thereof. The materials used in the drape may be hydrophobic or hydrophilic. Examples of suitable materials include Transeal® available from DeRoyal and OpSite® available from Smith & Nephew. In order to aid patient comfort and avoid skin maceration, the drapes in certain embodiments are at least partly breathable, such that water vapor is able to pass through without remaining trapped under the dressing. Lastly, although several embodiments illustrated herein illustrate an operator cutting an aperture into a drape manually, drapes used in the embodiments disclosed here may also be provided with one or more pre-cut apertures.
The wound is optionally filled with a wound packing material. Preferably, this wound packing material is conformable to the wound bed. This material is preferably soft and resiliently flexible. Examples of suitable forms of such wound fillers are foams formed of a suitable material, e.g. a resilient thermoplastic. Preferred materials for the present wound dressing include reticulated polyurethane foams with small apertures or pores and open-celled foams. Other suitable materials may include gauze. Preferably, such wound packing material will be able to channel wound exudate and other fluids through itself when negative pressure is applied to the wound. Some wound packing materials may include preformed channels or openings for such purposes.
Typically, the negative pressure wound treatment system is operated until a wound has reached a level of healing acceptable to a physician. The treatment system is preferably operated using a negative or reduced pressure ranging from about 40 to 200 mm Hg, though the amount may be lower or higher depending on physician preference. The time period for use of the wound treatment apparatus on a wound is selected by the physician. During the time period that negative pressure is applied, dressing changes and other temporary interruptions to the treatment may occur. Preferably, the negative pressure wound treatment system is able to handle at least 1 L of wound exudate or other fluid per day, or 0.694 ml/min. Some embodiments may handle over 10 L of wound exudate per day.
In preparing a wound site for treatment with the embodiments described herein, the wound is typically cleaned, debrided, and dried in a medically-acceptable manner. Optionally, the wound site may be filled partly or completely with a wound packing material 102 as shown in
Here, and with particular reference to
The upper and lower channel layers 5512 and 5516 are preferably elongate layers extending from the proximal end 5503 to the distal end 5505 and may each preferably comprise a porous material, including for example open-celled foams such as polyethylene or polyurethane. In some embodiments, one or more of the upper and lower channel layers 5512 and 5516 may be comprised of a fabric, for example a knitted or woven spacer fabric (such as a knitted polyester 3D fabric, Baltex 7970®, or Gehring 879®) or a nonwoven material. Suitable materials may also include terry-woven or loop-pile materials. The fibers may not necessarily be woven, and can include felted and flocked (including materials such as Flotex®) fibrous materials. The materials selected are preferably suited to channeling wound exudate away from the wound and for transmitting negative pressure and/or vented air to the wound site, and may also confer a degree of kinking or occlusion resistance to the channel layers 5512 and 5516 as described below. In one embodiment, the upper channel layer 5512 may comprise an open-celled foam such as polyurethane, and the lower channel layer may comprise a fabric as described herein. In another embodiment, the upper channel layer is optional, and the system may instead be provided with an open upper channel. In the embodiment illustrated in
In some embodiments, the fabric may have a three-dimensional structure, where one or more types of fibers form a structure where the fibers extend in all three dimensions. Such a fabric may in some cases aid in wicking, transporting fluid, and/or transmitting negative pressure. To prevent the channels 5512 and/or 5516 from being displaced or twisted while encased in the system 5501—which may impair performance of the respective channels under negative pressure—it may in some embodiments be preferable to adhere or otherwise secure the channels 5512 and/or 5516 to one or more of the layers 5510, 5514, and 5518. In certain embodiments, these materials remain open and capable of communicating negative pressure to a wound area under the typical pressures used in negative pressure therapy, for example between 40 to 150 mmHg, although higher and lower values are possible. In some embodiments, the fabric may comprise several layers of material stacked or layered over each other, which may in some cases be useful in preventing the channel 5516 from collapsing under the application of negative pressure. In other embodiments, the fabric used in channel 5516 may be between 1.5 mm and 6 mm; more preferably, the fabric may be between 3 mm and 6 mm thick, and may be comprised of either one or several individual layers of fabric. In other embodiments, the channel 5512 may be between 1.2-3 mm thick, and preferably thicker than 1.5 mm. Additionally, and as described previously, the materials used in the system 5501 are preferably conformable and soft, which may help to avoid pressure ulcers and other complications which may result from a wound treatment system being pressed against the skin of a patient. Further examples of 3D fabrics are discussed below in
Preferably, the distal ends of the layers 5510, 5514, and 5518 and the channel layers 5512 and 5516 are enlarged at their distal ends (to be placed over a wound site), and may form a “teardrop” or other enlarged shape. The distal ends of at least the layers 5512, 5514, 5516, and 5518 may also be provided with at least one through aperture. This aperture may be useful not only for the drainage of wound exudate and for applying negative pressure to the wound, but also during manufacturing of the device, as these apertures may be used to align these respective layers appropriately.
With additional reference to
The upper layer 5510 may comprise additional material extending downward, preferably at least of the thickness of the bridge 5502; this material may then be used to bond or weld to the other layers so to form a fluid-tight seal. More specifically, during assembly, the upper layer 5510 may be attached, for example by melting, welding, or with adhesives, to the lower layer 5518 so as to form a fluid-tight seal (with the exception of the apertures at the distal and proximal ends). Preferably, the middle layer 5514 is attached to the top layer 5510 and the bottom layer 5518. In some embodiments, it may be preferable to attach or bond the connectors 5504 and/or 5506, as well as the tube 5507 to at least one of the layers 5510, 5514, 5518 so as to create a fluid-tight connection. To provide for a more secure connection, some embodiments may also be provided with a weld 5532 made onto the lower layer 5518. The lower channel 5516 may have a hole or aperture made through it, which may be used to weld it, via the weld 5532, to the lower layer 5518. This welding of the lower channel 5516 to the lower layer 5518 via the weld 5532 made through the hole 5533 may thus aid in preventing the various layers and channels from shifting or being displaced. Obviously, it will be understood that other securement means may be used, for example adhesives and the like, and that such arrangements may be also be used in the upper channel 5512.
In certain embodiments, for example as illustrated in
The filter 5525 provided in the controlled air leak 5524 in certain embodiments may be useful in a system 5501 for use with more ambulatory and active patients. For example, a chemically-resistant filter may permit a patient to bathe or shower without damaging the filter's functionality when reconnected to a source of negative pressure. Any occlusion or fluid blocking the air leak 5524 could then be cleared by, for example, wiping off the filter 5525 or re-applying negative pressure to the system 5501. Such a system would also have the advantage that the system 5501 and any assorted wound dressing materials, if present, would not need to be removed and then re-applied should a patient need to be disconnected from the source of negative pressure, for example incidental to bathing. This would entail significant advantages in improving the cost-effectiveness and ease of use of the present treatment system.
The system 5501 is preferably constructed so as to provide a consistent fluid flow even if the system 5501 is kinked or weighted down. For example, in use on a patient, the bridge portion 5502 may become folded over itself, or else the patient may roll over, thus placing his or her weight over at least a portion of the system 5501. Typically, prior art dressings and fluidic connectors become blocked or ineffective in such situations and in some cases may contribute to complications such as pressure ulcers. Here, however, certain embodiments provide for improved blockage resistance if kinked or weighed down. Preferably, by employing channel layers 5512 and 5516 as described above, and more preferably by employing a foam channel layer 5512 and a fabric channel layer 5516, the system 5501 is able to maintain a flow rate through the air leak 5524 of at least 0.08 L/min, and preferably 0.12 L/min while negative pressure is applied through a source of negative pressure. Further embodiments also provide for the system 5501 to be able to handle fluid exudate drainage from the wound site through the lower channel 5516 of at least 10 L/day, or 6.9 ml/min. Certain embodiments provide for the system 5501 to maintain these flow rates with a weight, for example a 12 kg weight, pressing down on the bridge portion through a rod with a 1 in. diameter. In some embodiments, these flow rates are also maintained while the bridge portion 5502 is kinked over itself with the same weight, or for example with a 4.75 kg weight placed directly on the folded region. It is preferable that the system 5501 be able to withstand being folded or kinked over even during an extended period of time, for example over 40 hours, and not show any degradation in performance (e.g., flow rates) compared to its performance prior to being folded or kinked over. Preferably, embodiments of the system 5501 are also able to transmit and maintain a negative pressure at the wound that is close to the negative pressure level at the source of negative pressure. For example, an acceptable level of pressure maintained at the wound may be within ±25 mmHg of the negative pressure set at the source of negative pressure, with this pressure being preferably maintained at this level within 95% of the time that the system 5501 has negative pressure applied to it. Acceptable pressure levels may include pressure ranges between 40-120 mmHg, although levels of 200 mmHg have successfully been used.
With additional reference to
In use, and with reference to
During use of the system 5501, wound exudate from the wound site 5530 is drawn by the negative pressure through the lower channel layer 5516. The air leak 5524 allows air to pass through the upper channel layer 5512 into the apertures through the distal ends of the layers 5512, 5514, 5516 and 5518. The negative pressure draws air passing through the upper channel layer into the lower channel layer 5516 back toward the source of negative pressure or pump. In some embodiments, the controlled air leak 5524 provides a constant flow of air through the system 5501, which then may be used to determine whether blockage or leakage is present. Causes of blockage can include, for example, situations where the lower channel 5516 becomes occluded with wound debris. Leakage causes can include, for example, improper sealing of the drape over the wound site, or physical damage to the system 5501 leading to excess air leaking into the system. The blockage or leakage may be determined, in certain embodiments, by measuring the speed of the pump while the pump works to maintain a constant negative pressure. Pump speed may also be measured indirectly by measuring the amount of voltage or signal sent to the pump.
In one embodiment, as illustrated in
It will often be advantageous to tailor the performance characteristics of the 3D fabric while in use to account for various requirements of the suction adapter. In particular, the flow rate of exudate through the fabric, for example when under compression, may be simplified by considering the porosity of the fabric. In such situations, and again without wishing to be bound by theory, the porosity of the fabric, and thus the space that will be available for fluids to travel through, may be determined in part by the knit pattern of the fibers used in creating the 3D fabric, the thickness of the fibers used therein, and their respective stiffness and hardness (especially when under compression). Fibers may also be modified by surface properties (the fibers can be flat or textured) and the number of fibers or filaments used in the resulting fabric. Compression resistance may be affected by the choice of fiber or monofilament used in the vertical axis of the fabric, and generally, a stiffer material will improve compression resistance on this axis. Other materials properties, such as hydrophobicity, may play a role. In some cases, it may be beneficial to treat the fabric to be hydrophilic, for example with a hydrophilic polymer, so as to improve wicking of fluids. Preferred embodiments of the 3D fabric used with certain suction adapters have been found to work well when Baltex® fabric is treated in such a fashion. Other possible treatments may include lipophilic coatings to prevent proteins from adhering and building up during use, which may cause clogging and loss of pressure to the wound site.
The flow rate through the 3D fabric while under the application of negative pressure may be approximated by considering each opening as a separate orifice plate subject to Bernoulli's principle while under laminar flow. To simplify calculations, the area of openings for a given area of 3D fabric may be used. Thus, the 3D fabric may be optimized to achieve a good balance between factors such as the compression resistance required and the resulting flow rate under the application of negative pressure. Further optimization will also take place with the stiffness and flow rate of the 3D fabric being tailored to application in the embodiments described herein. Optimization of the properties and dimensions of the 3D fabric will also preferably take into account a balancing between the flow rate and stiffness required and the conformability of the fabric, as a fabric that is too stiff may not bend appropriately and may also be uncomfortable on the patient. The 3D fabric should preferably be designed so as to yield when compressed against tissue, thereby preventing tissue compression (for example against bony prominences in the patient) and the discomfort and damage, such as pressure ulcers, that may follow. For example, the dimensions of the fabric may be tailored for the ultimate use of the suction adapter—smaller in the case of distal extremities such as fingers, and larger for abdominal and burn wounds. A fabric that is too stiff may also cause pressure ulcers and other such complications, although it may function acceptably in larger dimensions.
In practice, and as also described previously herein, flow rates through embodiments of the suction adapter using 3D fabrics are at least 0.08 L/min, preferably up to 10 L/min during the application of negative pressure, and should be able to handle fluid exudate drainage of at least 10 L/day. Some embodiments of the suction adapter may be configured to handle much larger wounds, including abdominal wounds, and which in some cases may exude at least 0.5 L/hr, or 12 L/day. In more extreme cases, the pump used (for example, the RENASYS EZ) may be able to evacuate up to 16 L/min, thereby evacuating a large wound to a negative pressure level of 120 mmHg in less than a minute. The pressure drop calculated due to the 3D fabric should be minimal, and the level of negative pressure measured at a wound site is preferably within 25 mmHg of the pressure level measured at the source of negative pressure. Although the pressure drop increases as the negative pressure applied increases (thus rendering the 25 mmHg target more difficult to reach), embodiments of the wound treatment system are preferably able to maintain this target pressure to at least a negative pressure of 200 mmHg. The suction adapter and system are preferably able to function within pressure ranges required for negative pressure, which are estimated to be from around 40 mmHg to 200 mmHg. Pressure ranges greater than 200 mmHg are possible, but these may in some circumstances cause patient discomfort. The apparatus may also function at lower pressure ranges, such as 20 mmHg, although at such low pressure levels the therapeutic effects resulting from negative pressure may be diminished, with the device acting more as a drainage device. Preferably, embodiments of a negative pressure treatment system are able to maintain these target pressures at the wound site within 95% of the time that negative pressure is being applied to the wound. In some embodiments, the fabric may comprise several layers of material stacked or layered over each other, which may in some cases be useful in preventing the channel 5516 from collapsing under the application of negative pressure. In other embodiments, the fabric used in channel 5516 may be between 1.5 mm and 6 mm; more preferably, the fabric may be between 3 mm and 6 mm thick, and may be comprised of either one or several individual layers of fabric. In other embodiments, the channel 5512 may be between 1.2-3 mm thick, and preferably thicker than 1.5 mm. Preferably, the 3D fabric is able to withstand a load of at least 5.3 psi with a compression of not more than 10% of the fabric's original thickness. Further, the 3D fabric may also be able to resist compression to less than half of its original thickness when subjected to a load of 15 psi.
In a preferred embodiment, a 3D fabric may be woven from 100% polyester using yarns of 150 and 225 Denier, to yield a fabric weighing approximately 23 to 25 oz per square yard. In these cases, the fabric may be approximately 5.8-6.8 mm thick. The bottom portion of the fabric may also have several openings or pores 5611 similar to those illustrated in
Embodiments of the systems described herein have been tested and found to perform satisfactorily. Such testing was performed by constructing suction adapters from embodiments described herein. The distal ends of the suction adapters were then placed over an aperture made onto a drape placed over a simulated wound cavity provided with a source of simulated wound fluid, which was controllable and which can vary the flow rate of the wound fluid. The simulated wound cavity was also in some cases packed with foam or some other wound packing material. In some tests, the simulated wound fluid was a 5:1 water to glycerol mix, and in others filtered horse serum (available from Oxoid, United Kingdom) was used. The proximal end of the suction adapter was then connected to a source of negative pressure, in this case a pump. Flow rate tests and other measurements were then conducted at various negative pressure ranges and simulated exudate flow rates and air leak rates.
In
In
The distal projections 5852 may include two or more projections 5852 extending distally lengthwise from the preferably cylindrical main body 5804 of the connector 5800. These projections 5852 may additionally comprise one or more barbs 5854 attached thereto. For example, two barbs 5854 are shown on each of the projections in
The proximal portion of the projections 5852 may also comprise a reinforcing portion 5858 connecting the projections 5852 to the main body 5804, and which may be configured to provide additional strength. As illustrated in
In some embodiments, the distal end of the cylindrical body 5804 along its outer surface may be provided with an enlarged shoulder 5859, which is preferably rounded when viewed in profile in
At the proximal end of the connector 5800, a lip 5856, which may be provided in a frustoconical form, may also be used for connection to a tube 5840. In some embodiments, the lip 5856 may have a rounded proximal edge that may facilitate connecting to the tube 5840. As illustrated, in one embodiment the lip 5856 increases in outer dimension from its proximal end toward its distal end. At the distal end of the lip 5856, there is a step-down in outer dimension to the main cylindrical body 5804. The tube 5840 may be connected to the connector 5800 (as well as the other connectors described herein) for example by press-fitting, although other connections means are possible.
With reference to
Although preferred dimensions have been provided for one embodiment of a connector 5800, it will be appreciated that connectors for use in negative pressure with other dimensions are also contemplated. This includes connectors having a length (including projections) of between 0.5 to 3 inches (between or about 0.5 to about 3 inches) and an inner diameter (of the central channel 5855) of between 0.05 to 1 inch. Suitable materials for the connector 5800 may include polymers, for example but without limitation polymers such as polypropylene, polyethylene, polystyrene, and blends thereof.
With reference again to
In some embodiments, the pulling force required to dislodge or disconnect any of the connectors described above may be optimized to provide a safety feature. For example, should an embodiment of the negative pressure treatment system 5502 become entangled or trapped while applied to a patient, the pulling force can be tailored so that a connector such as connector 5800 disconnects from the channel 5516 under such force. When the connector 5800 disconnects from the channel 5516, a separation may form between the connector and the channel layer. The layers 5514 and 5518 from the embodiment illustrated in
The preceding embodiments illustrated in
While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it will be understood that various omissions, substitutions, and changes in the form and details of the device or process illustrated may be made without departing from the spirit of the disclosure. Additionally, the various features and processes described above may be used independently of one another, or may be combined in various ways. All possible combinations and subcombinations are intended to fall within the scope of this disclosure. Many of the embodiments described above include similar components, and as such, these similar components can be interchanged in different embodiments.
Although the invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof. Accordingly, the invention is not intended to be limited by the specific disclosures of preferred embodiments herein.
This application is a continuation of U.S. application Ser. No. 14/730,040, filed Jun. 3, 2015, which is a continuation of U.S. application Ser. No. 13/381,884, filed Jul. 12, 2013, which is a U.S. National Phase of the PCT International Application No. PCT/US2011/041521 filed on Jun. 22, 2011, designating the United States, which claims priority to U.S. Provisional Application Ser. No. 61/426,432, filed Dec. 22, 2010. The disclosure of each of these prior applications is incorporated by reference in its entirety and should be considered a part of this specification.
Number | Name | Date | Kind |
---|---|---|---|
1585104 | Montgomery | May 1926 | A |
2736317 | Alexander | Feb 1956 | A |
3042041 | Jascalevich | Jul 1962 | A |
3255749 | Smithers | Jun 1966 | A |
3568675 | Harvey | Mar 1971 | A |
3572340 | Lloyd et al. | Mar 1971 | A |
3874387 | Barbieri | Apr 1975 | A |
3880164 | Stepno | Apr 1975 | A |
3927443 | Brumlik | Dec 1975 | A |
3943734 | Fleissner | Mar 1976 | A |
4080970 | Miller | Mar 1978 | A |
4117551 | Brooks et al. | Sep 1978 | A |
4164027 | Bonnie et al. | Aug 1979 | A |
4169303 | Lemelson | Oct 1979 | A |
4231357 | Hessner | Nov 1980 | A |
4261363 | Russo | Apr 1981 | A |
4360015 | Mayer | Nov 1982 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4468219 | George et al. | Aug 1984 | A |
4538920 | Drake | Sep 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4553967 | Ferguson et al. | Nov 1985 | A |
4561435 | McKnight et al. | Dec 1985 | A |
4569674 | Phillips | Feb 1986 | A |
4579120 | MacGregor | Apr 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4614183 | McCracken et al. | Sep 1986 | A |
4665909 | Trainor | May 1987 | A |
4753536 | Spehar et al. | Jun 1988 | A |
4767026 | Keller et al. | Aug 1988 | A |
4771919 | Ernst | Sep 1988 | A |
4872450 | Austad | Oct 1989 | A |
4906240 | Reed et al. | Mar 1990 | A |
4921492 | Schultz | May 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4980226 | Hellgren et al. | Dec 1990 | A |
5009224 | Cole | Apr 1991 | A |
5056510 | Gilman | Oct 1991 | A |
5060642 | Gilman | Oct 1991 | A |
5064653 | Sessions et al. | Nov 1991 | A |
5080493 | McKown et al. | Jan 1992 | A |
5088483 | Heinecke | Feb 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5106362 | Gilman | Apr 1992 | A |
5112323 | Winkler et al. | May 1992 | A |
5134007 | Reising et al. | Jul 1992 | A |
5139023 | Stanley et al. | Aug 1992 | A |
5147698 | Cole | Sep 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5152757 | Eriksson | Oct 1992 | A |
5160315 | Heinecke et al. | Nov 1992 | A |
5160334 | Billings et al. | Nov 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5180375 | Feibus | Jan 1993 | A |
5218973 | Weaver | Jun 1993 | A |
5230496 | Shillington et al. | Jul 1993 | A |
5244457 | Karami et al. | Sep 1993 | A |
5249709 | Duckworth et al. | Oct 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5263922 | Sova et al. | Nov 1993 | A |
5300054 | Feist et al. | Apr 1994 | A |
5304161 | Noel et al. | Apr 1994 | A |
5308313 | Karami et al. | May 1994 | A |
5333760 | Simmen | Aug 1994 | A |
5358492 | Feibus | Oct 1994 | A |
5366451 | Levesque | Nov 1994 | A |
5391161 | Hellgren et al. | Feb 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5439458 | Noel et al. | Aug 1995 | A |
5447492 | Cartmell et al. | Sep 1995 | A |
5486167 | Dragoo et al. | Jan 1996 | A |
5520629 | Heinecke et al. | May 1996 | A |
5525407 | Yang | Jun 1996 | A |
5527293 | Zamierowski | Jun 1996 | A |
5527923 | Klingler et al. | Jun 1996 | A |
5531855 | Heinecke et al. | Jul 1996 | A |
5549584 | Gross | Aug 1996 | A |
5582596 | Fukunaga et al. | Dec 1996 | A |
5593750 | Rothrum et al. | Jan 1997 | A |
5599289 | Castellana | Feb 1997 | A |
5603145 | Arakawa | Feb 1997 | A |
5609271 | Keller et al. | Mar 1997 | A |
5613942 | Lucast et al. | Mar 1997 | A |
5618278 | Rothrum | Apr 1997 | A |
5618556 | Johns et al. | Apr 1997 | A |
5624423 | Anjur et al. | Apr 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5637093 | Hyman et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5678564 | Lawrence et al. | Oct 1997 | A |
5695846 | Lange et al. | Dec 1997 | A |
5701917 | Khouri | Dec 1997 | A |
5738642 | Heinecke et al. | Apr 1998 | A |
5738656 | Wagner | Apr 1998 | A |
5795584 | Totakura et al. | Aug 1998 | A |
5797844 | Yoshioka et al. | Aug 1998 | A |
5797894 | Cadieux et al. | Aug 1998 | A |
5885237 | Kadash et al. | Mar 1999 | A |
5894608 | Birbara | Apr 1999 | A |
5910150 | Saadat | Jun 1999 | A |
5911222 | Lawrence et al. | Jun 1999 | A |
5914282 | Dunshee et al. | Jun 1999 | A |
5928265 | Fleischmann | Jul 1999 | A |
5964723 | Augustine | Oct 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6117111 | Fleischmann | Sep 2000 | A |
6121508 | Bischof et al. | Sep 2000 | A |
6142982 | Hunt et al. | Nov 2000 | A |
6149614 | Dunshee et al. | Nov 2000 | A |
6169224 | Heinecke et al. | Jan 2001 | B1 |
6252129 | Coffee | Jun 2001 | B1 |
6264976 | Heinecke et al. | Jul 2001 | B1 |
6291050 | Cree et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6391294 | Dettmar et al. | May 2002 | B1 |
6398761 | Bills et al. | Jun 2002 | B1 |
6406447 | Thrash et al. | Jun 2002 | B1 |
6420622 | Johnston et al. | Jul 2002 | B1 |
6436432 | Heinecke et al. | Aug 2002 | B2 |
6458109 | Henley et al. | Oct 2002 | B1 |
6461467 | Blatchford et al. | Oct 2002 | B2 |
6471685 | Johnson | Oct 2002 | B1 |
6479073 | Lucast et al. | Nov 2002 | B1 |
6486285 | Fujita | Nov 2002 | B2 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6566575 | Stickels et al. | May 2003 | B1 |
6607799 | Heinecke et al. | Aug 2003 | B1 |
6626891 | Ohmstede | Sep 2003 | B2 |
6629774 | Gruendeman | Oct 2003 | B1 |
6648862 | Watson | Nov 2003 | B2 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6685682 | Heinecke et al. | Feb 2004 | B1 |
6752794 | Lockwood et al. | Jun 2004 | B2 |
6755807 | Risk et al. | Jun 2004 | B2 |
6800074 | Henley et al. | Oct 2004 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
6824533 | Risk, Jr. et al. | Nov 2004 | B2 |
6838589 | Liedtke et al. | Jan 2005 | B2 |
6855135 | Lockwood et al. | Feb 2005 | B2 |
6867342 | Johnston et al. | Mar 2005 | B2 |
6878857 | Chihani et al. | Apr 2005 | B1 |
6903243 | Burton | Jun 2005 | B1 |
6936037 | Bubb et al. | Aug 2005 | B2 |
6951553 | Bubb et al. | Oct 2005 | B2 |
D515701 | Horhota et al. | Feb 2006 | S |
6994702 | Johnson | Feb 2006 | B1 |
6994904 | Joseph et al. | Feb 2006 | B2 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7005143 | Abuelyaman et al. | Feb 2006 | B2 |
7048818 | Krantz | May 2006 | B2 |
7070580 | Nielsen | Jul 2006 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7108683 | Zamierowski | Sep 2006 | B2 |
7117869 | Heaton et al. | Oct 2006 | B2 |
7128735 | Weston | Oct 2006 | B2 |
7183454 | Rosenberg | Feb 2007 | B1 |
7195624 | Lockwood | Mar 2007 | B2 |
7198046 | Argenta et al. | Apr 2007 | B1 |
7216651 | Argenta et al. | May 2007 | B2 |
7273054 | Heaton et al. | Sep 2007 | B2 |
7276247 | Fansler et al. | Oct 2007 | B2 |
7279612 | Heaton et al. | Oct 2007 | B1 |
7285576 | Hyde et al. | Oct 2007 | B2 |
7316672 | Hunt et al. | Jan 2008 | B1 |
7338482 | Lockwood et al. | Mar 2008 | B2 |
7381859 | Hunt et al. | Jun 2008 | B2 |
7438705 | Karpowicz et al. | Oct 2008 | B2 |
7442849 | Heinecke | Oct 2008 | B2 |
7485112 | Karpowicz et al. | Feb 2009 | B2 |
7503910 | Adahan | Mar 2009 | B2 |
7531711 | Sigurjonsson et al. | May 2009 | B2 |
7534927 | Lockwood | May 2009 | B2 |
7569742 | Haggstrom et al. | Aug 2009 | B2 |
7585554 | Johnson et al. | Sep 2009 | B2 |
7586019 | Oelund et al. | Sep 2009 | B2 |
7615036 | Joshi et al. | Nov 2009 | B2 |
7625362 | Boehringer et al. | Dec 2009 | B2 |
7645269 | Zamierowski | Jan 2010 | B2 |
7651484 | Heaton et al. | Jan 2010 | B2 |
7670323 | Hunt et al. | Mar 2010 | B2 |
7678102 | Heaton | Mar 2010 | B1 |
7686785 | Boehringer et al. | Mar 2010 | B2 |
7699831 | Bengtson et al. | Apr 2010 | B2 |
7717313 | Criscuolo et al. | May 2010 | B2 |
7723560 | Lockwood | May 2010 | B2 |
7745681 | Ferguson | Jun 2010 | B1 |
7754937 | Boehringer et al. | Jul 2010 | B2 |
7758554 | Lina et al. | Jul 2010 | B2 |
7759537 | Bishop et al. | Jul 2010 | B2 |
7759539 | Shaw et al. | Jul 2010 | B2 |
7776028 | Miller et al. | Aug 2010 | B2 |
7779625 | Joshi et al. | Aug 2010 | B2 |
7781639 | Johnston et al. | Aug 2010 | B2 |
7790945 | Watson, Jr. | Sep 2010 | B1 |
7790946 | Mulligan | Sep 2010 | B2 |
7794438 | Henley et al. | Sep 2010 | B2 |
7794450 | Blott | Sep 2010 | B2 |
7803980 | Griffiths et al. | Sep 2010 | B2 |
7815616 | Boehringer et al. | Oct 2010 | B2 |
7846141 | Weston | Dec 2010 | B2 |
7857806 | Karpowicz et al. | Dec 2010 | B2 |
7862718 | Doyen et al. | Jan 2011 | B2 |
7880050 | Robinson | Feb 2011 | B2 |
7896823 | Mangrum et al. | Mar 2011 | B2 |
7896856 | Petrosenko et al. | Mar 2011 | B2 |
7896864 | Lockwood et al. | Mar 2011 | B2 |
7922703 | Riesinger | Apr 2011 | B2 |
7942866 | Radl | May 2011 | B2 |
7951124 | Boehringer et al. | May 2011 | B2 |
7976533 | Larsson | Jul 2011 | B2 |
7981098 | Boehringer et al. | Jul 2011 | B2 |
8002313 | Singh et al. | Aug 2011 | B2 |
8007257 | Heaton et al. | Aug 2011 | B2 |
8008538 | Ugander et al. | Aug 2011 | B2 |
8021347 | Vitaris et al. | Sep 2011 | B2 |
8057449 | Sanders et al. | Nov 2011 | B2 |
8061360 | Locke et al. | Nov 2011 | B2 |
8083712 | Biggie et al. | Dec 2011 | B2 |
8097272 | Addison | Jan 2012 | B2 |
8100887 | Weston et al. | Jan 2012 | B2 |
8114126 | Heaton | Feb 2012 | B2 |
8133211 | Cavanaugh, II et al. | Mar 2012 | B2 |
8142419 | Heaton | Mar 2012 | B2 |
8147468 | Barta et al. | Apr 2012 | B2 |
8148595 | Robinson et al. | Apr 2012 | B2 |
8148596 | Miau et al. | Apr 2012 | B2 |
8152785 | Vitaris | Apr 2012 | B2 |
8158844 | McNeil | Apr 2012 | B2 |
8162907 | Heagle | Apr 2012 | B2 |
8168848 | Lockwood et al. | May 2012 | B2 |
8177764 | Hu et al. | May 2012 | B2 |
8188331 | Barta et al. | May 2012 | B2 |
8192409 | Hardman | Jun 2012 | B2 |
8197467 | Heaton | Jun 2012 | B2 |
8202261 | Kazala, Jr. et al. | Jun 2012 | B2 |
8235939 | Johnson et al. | Aug 2012 | B2 |
8241261 | Randolph et al. | Aug 2012 | B2 |
8298200 | Vess et al. | Oct 2012 | B2 |
8372049 | Jaeb et al. | Feb 2013 | B2 |
8382731 | Johannison | Feb 2013 | B2 |
D679819 | Peron | Apr 2013 | S |
D679820 | Peron | Apr 2013 | S |
8409170 | Locke et al. | Apr 2013 | B2 |
8439893 | Wakabayashi | May 2013 | B2 |
8608776 | Coward | Dec 2013 | B2 |
8623047 | Cornet | Jan 2014 | B2 |
8690845 | Long et al. | Apr 2014 | B2 |
8708998 | Weston et al. | Apr 2014 | B2 |
8721629 | Hardman | May 2014 | B2 |
8734410 | Hall et al. | May 2014 | B2 |
8771244 | Eckstein et al. | Jul 2014 | B2 |
8784392 | Vess et al. | Jul 2014 | B2 |
8801685 | Armstrong | Aug 2014 | B2 |
8814842 | Coulthard et al. | Aug 2014 | B2 |
D714433 | Armstrong et al. | Sep 2014 | S |
8843327 | Vernon-Harcourt et al. | Sep 2014 | B2 |
8870837 | Locke et al. | Oct 2014 | B2 |
8905985 | Allen et al. | Dec 2014 | B2 |
8951235 | Allen et al. | Feb 2015 | B2 |
9017302 | Vitaris et al. | Apr 2015 | B2 |
9050398 | Armstrong | Jun 2015 | B2 |
9061095 | Adie et al. | Jun 2015 | B2 |
D746435 | Armstrong et al. | Dec 2015 | S |
RE45864 | Peron | Jan 2016 | E |
9227000 | Fink et al. | Jan 2016 | B2 |
9327065 | Albert | May 2016 | B2 |
9474654 | Heagle et al. | Oct 2016 | B2 |
RE46289 | Peron | Jan 2017 | E |
9539373 | Jones et al. | Jan 2017 | B2 |
9642750 | Albert | May 2017 | B2 |
9681993 | Wu et al. | Jun 2017 | B2 |
D804014 | Armstrong et al. | Nov 2017 | S |
RE46825 | Heagle | May 2018 | E |
9956389 | Armstrong | May 2018 | B2 |
9974695 | Albert | May 2018 | B2 |
9999547 | Albert | Jun 2018 | B2 |
10065030 | Kantrowitz et al. | Sep 2018 | B2 |
10406037 | Albert | Sep 2019 | B2 |
RE48117 | Albert | Jul 2020 | E |
10744239 | Armstrong | Aug 2020 | B2 |
20010034223 | Rieser et al. | Oct 2001 | A1 |
20020002209 | Mork | Jan 2002 | A1 |
20020182246 | Oyaski | Dec 2002 | A1 |
20030050594 | Zamierowski | Mar 2003 | A1 |
20030171675 | Rosenberg | Sep 2003 | A1 |
20030225347 | Argenta et al. | Dec 2003 | A1 |
20040039415 | Zamierowski | Feb 2004 | A1 |
20040054338 | Bybordi | Mar 2004 | A1 |
20040064132 | Boehringer et al. | Apr 2004 | A1 |
20050004534 | Lockwood | Jan 2005 | A1 |
20050020955 | Sanders et al. | Jan 2005 | A1 |
20050065484 | Watson, Jr. | Mar 2005 | A1 |
20050085795 | Lockwood | Apr 2005 | A1 |
20050101940 | Radl et al. | May 2005 | A1 |
20050137539 | Biggie et al. | Jun 2005 | A1 |
20050273066 | Wittmann | Dec 2005 | A1 |
20060009744 | Edrman et al. | Jan 2006 | A1 |
20060036221 | Watson, Jr. | Feb 2006 | A1 |
20060079852 | Bubb et al. | Apr 2006 | A1 |
20060100586 | Karpowicz | May 2006 | A1 |
20070038172 | Zamierowski | Feb 2007 | A1 |
20070129707 | Blott | Jun 2007 | A1 |
20070156104 | Lockwood et al. | Jul 2007 | A1 |
20070167927 | Hunt et al. | Jul 2007 | A1 |
20070219497 | Johnson et al. | Sep 2007 | A1 |
20070219512 | Heaton | Sep 2007 | A1 |
20070233022 | Henley et al. | Oct 2007 | A1 |
20070260226 | Jaeb | Nov 2007 | A1 |
20080033325 | Van der Hulst et al. | Feb 2008 | A1 |
20080103489 | Dahners | May 2008 | A1 |
20080161778 | Steward | Jul 2008 | A1 |
20080167593 | Fleischmann | Jul 2008 | A1 |
20080195017 | Robinson | Aug 2008 | A1 |
20080200906 | Sanders et al. | Aug 2008 | A1 |
20080208147 | Argenta et al. | Aug 2008 | A1 |
20080243096 | Svedman | Oct 2008 | A1 |
20080275409 | Kane et al. | Nov 2008 | A1 |
20080281281 | Meyer et al. | Nov 2008 | A1 |
20080287892 | Khan et al. | Nov 2008 | A1 |
20080294147 | Radi et al. | Nov 2008 | A1 |
20080300578 | Freedman | Dec 2008 | A1 |
20080306456 | Riesinger | Dec 2008 | A1 |
20090005744 | Karpowicz et al. | Jan 2009 | A1 |
20090012501 | Boehringer et al. | Jan 2009 | A1 |
20090043268 | Eddy | Feb 2009 | A1 |
20090093778 | Svedman | Apr 2009 | A1 |
20090099519 | Kaplan | Apr 2009 | A1 |
20090124988 | Coulthard | May 2009 | A1 |
20090131892 | Karpowicz et al. | May 2009 | A1 |
20090137973 | Karpowicz et al. | May 2009 | A1 |
20090157016 | Adahan | Jun 2009 | A1 |
20090171288 | Wheeler | Jul 2009 | A1 |
20090204085 | Biggie | Aug 2009 | A1 |
20090227968 | Vess | Sep 2009 | A1 |
20090264837 | Adahan | Oct 2009 | A1 |
20090264838 | Livne | Oct 2009 | A1 |
20090281526 | Kenny et al. | Nov 2009 | A1 |
20090287133 | LaGreca, Sr. | Nov 2009 | A1 |
20090293887 | Wilkes et al. | Dec 2009 | A1 |
20090299249 | Wilkes et al. | Dec 2009 | A1 |
20090299251 | Buan | Dec 2009 | A1 |
20090299255 | Kazala, Jr. et al. | Dec 2009 | A1 |
20090299257 | Long et al. | Dec 2009 | A1 |
20090299303 | Seegert | Dec 2009 | A1 |
20090299308 | Kazala et al. | Dec 2009 | A1 |
20090299340 | Kazala et al. | Dec 2009 | A1 |
20090312723 | Blott | Dec 2009 | A1 |
20100000524 | Ohbi | Jan 2010 | A1 |
20100036334 | Heagle | Feb 2010 | A1 |
20100069850 | Fabo | Mar 2010 | A1 |
20100069858 | Olson | Mar 2010 | A1 |
20100069863 | Olson | Mar 2010 | A1 |
20100069885 | Stevenson et al. | Mar 2010 | A1 |
20100087767 | McNeil | Apr 2010 | A1 |
20100094234 | Ramella et al. | Apr 2010 | A1 |
20100106106 | Heaton | Apr 2010 | A1 |
20100106114 | Weston | Apr 2010 | A1 |
20100106121 | Holm | Apr 2010 | A1 |
20100125258 | Coulthard et al. | May 2010 | A1 |
20100152639 | Miau et al. | Jun 2010 | A1 |
20100160878 | Hunt et al. | Jun 2010 | A1 |
20100160901 | Hu et al. | Jun 2010 | A1 |
20100174250 | Hu | Jul 2010 | A1 |
20100185163 | Heagle | Jul 2010 | A1 |
20100191197 | Braga | Jul 2010 | A1 |
20100191198 | Heagle | Jul 2010 | A1 |
20100210986 | Sanders | Aug 2010 | A1 |
20100262091 | Larsson | Oct 2010 | A1 |
20100268128 | Randolph | Oct 2010 | A1 |
20100305524 | Vess | Dec 2010 | A1 |
20100324510 | Andresen et al. | Dec 2010 | A1 |
20100324516 | Braga | Dec 2010 | A1 |
20110028919 | Johnnison et al. | Feb 2011 | A1 |
20110125066 | Robinson et al. | May 2011 | A1 |
20110125110 | Cotton | May 2011 | A1 |
20110130712 | Topaz | Jun 2011 | A1 |
20110172582 | Darian | Jul 2011 | A1 |
20110230849 | Coulthard | Sep 2011 | A1 |
20110245682 | Robinson et al. | Oct 2011 | A1 |
20120116334 | Albert | May 2012 | A1 |
20120143156 | Bannister et al. | Jun 2012 | A1 |
20120302976 | Locke et al. | Nov 2012 | A1 |
20130066284 | Croizat | Mar 2013 | A1 |
20130066286 | Croizat | Mar 2013 | A1 |
20130066365 | Belson | Mar 2013 | A1 |
20130144230 | Wu | Jun 2013 | A1 |
20130172835 | Braga et al. | Jul 2013 | A1 |
20130204213 | Heagle | Aug 2013 | A1 |
20130253453 | Olson | Sep 2013 | A1 |
20130310809 | Armstrong | Nov 2013 | A1 |
20140330224 | Albert | Nov 2014 | A1 |
20140343520 | Bennett et al. | Nov 2014 | A1 |
20150073358 | Jaeb et al. | Mar 2015 | A1 |
20150343194 | Armstrong | Dec 2015 | A1 |
20160151548 | Albert | Jun 2016 | A1 |
20160375184 | Albert | Dec 2016 | A1 |
20170035617 | Albert | Feb 2017 | A1 |
20170216501 | Armstrong | Aug 2017 | A1 |
20180028365 | Albert | Feb 2018 | A1 |
20180304065 | Armstrong | Oct 2018 | A1 |
20180308578 | Armstrong | Oct 2018 | A1 |
20190380881 | Albert | Dec 2019 | A1 |
20200100945 | Albert | Apr 2020 | A1 |
20200289723 | Gregory | Sep 2020 | A1 |
Number | Date | Country |
---|---|---|
674837 | Jan 1997 | AU |
3 907 007 | Sep 1990 | DE |
20 2010 009 148 | Oct 2010 | DE |
0 325 771 | Sep 1993 | EP |
0 392 640 | Jun 1995 | EP |
0 441 418 | Jul 1995 | EP |
0 465 601 | Jan 1997 | EP |
0 751 757 | Jan 1997 | EP |
0 692 987 | Oct 1997 | EP |
0 853 950 | Jul 1998 | EP |
0 651 983 | Sep 1998 | EP |
0 777 504 | Oct 1998 | EP |
0 782 421 | Jul 1999 | EP |
1 018 967 | Jul 2000 | EP |
0 690 706 | Nov 2000 | EP |
1 129 734 | Sep 2001 | EP |
0 921 775 | Dec 2001 | EP |
1 169 071 | Jan 2002 | EP |
0 708 620 | May 2003 | EP |
1 014 905 | May 2003 | EP |
1 088 569 | Aug 2003 | EP |
0 993 317 | Sep 2003 | EP |
0 880 953 | Oct 2003 | EP |
1 219 311 | Jul 2004 | EP |
1 440 667 | Jul 2004 | EP |
1 448 261 | Aug 2004 | EP |
1 100 574 | Feb 2005 | EP |
0 688 189 | Jun 2005 | EP |
1 284 777 | Apr 2006 | EP |
0 982 015 | Aug 2006 | EP |
0 620 720 | Nov 2006 | EP |
1 227 853 | Jan 2008 | EP |
1 476 217 | Mar 2008 | EP |
1906903 | Apr 2008 | EP |
1 920 791 | May 2008 | EP |
1 233 808 | Jul 2008 | EP |
1977776 | Oct 2008 | EP |
1993491 | Nov 2008 | EP |
1 827 561 | Jan 2009 | EP |
2 052 750 | Apr 2009 | EP |
2 098 257 | Sep 2009 | EP |
2 103 290 | Sep 2009 | EP |
2 127 690 | Dec 2009 | EP |
2138139 | Dec 2009 | EP |
1 652 549 | Jan 2010 | EP |
1 905 465 | Jan 2010 | EP |
2203137 | Jul 2010 | EP |
2 218 431 | Aug 2010 | EP |
2244217 | Oct 2010 | EP |
2244746 | Nov 2010 | EP |
1 703 922 | May 2011 | EP |
2 319 550 | May 2011 | EP |
2 349 155 | Aug 2011 | EP |
1 578 477 | Sep 2011 | EP |
1 763 378 | Dec 2011 | EP |
2 529 766 | Dec 2012 | EP |
2 659 915 | Nov 2013 | EP |
2 628 500 | May 2014 | EP |
2307180 | May 1997 | GB |
2336546 | Oct 1999 | GB |
2344531 | Jul 2000 | GB |
2356148 | May 2001 | GB |
2431351 | Apr 2007 | GB |
H04-503625 | Jul 1992 | JP |
H08-098706 | Apr 1996 | JP |
2001314479 | Nov 2001 | JP |
WO 199403214 | Feb 1994 | WO |
WO 199421207 | Sep 1994 | WO |
WO 199423678 | Oct 1994 | WO |
WO 199901173 | Jan 1999 | WO |
WO 2000007653 | Feb 2000 | WO |
WO 200061206 | Oct 2000 | WO |
WO 2000064394 | Nov 2000 | WO |
WO 2001085228 | Nov 2001 | WO |
WO 2001085248 | Nov 2001 | WO |
WO 2002043634 | Jun 2002 | WO |
WO 2002070040 | Sep 2002 | WO |
WO-02092783 | Nov 2002 | WO |
WO 2003086232 | Oct 2003 | WO |
WO 2003101508 | Dec 2003 | WO |
WO 2004018020 | Mar 2004 | WO |
WO 2004037334 | May 2004 | WO |
WO 2004041064 | May 2004 | WO |
WO 2004060148 | Jul 2004 | WO |
WO 2005009488 | Feb 2005 | WO |
WO 2005016179 | Feb 2005 | WO |
WO 2005025447 | Mar 2005 | WO |
WO 2005046760 | May 2005 | WO |
WO 2005046761 | May 2005 | WO |
WO 2005046762 | May 2005 | WO |
WO 2005051461 | Jun 2005 | WO |
WO 2005061025 | Jul 2005 | WO |
WO 2005072789 | Aug 2005 | WO |
WO 2005079718 | Sep 2005 | WO |
WO 2005102415 | Nov 2005 | WO |
WO 2005105174 | Nov 2005 | WO |
WO 2005105175 | Nov 2005 | WO |
WO 2005105176 | Nov 2005 | WO |
WO 2005105179 | Nov 2005 | WO |
WO 2005105180 | Nov 2005 | WO |
WO 2005107842 | Nov 2005 | WO |
WO 2005115497 | Dec 2005 | WO |
WO 2005115523 | Dec 2005 | WO |
WO 2005123170 | Dec 2005 | WO |
WO 2006046060 | May 2006 | WO |
WO 2006052338 | May 2006 | WO |
WO 2006052745 | May 2006 | WO |
WO 2006114637 | Nov 2006 | WO |
WO 2006114638 | Nov 2006 | WO |
WO 2006114648 | Nov 2006 | WO |
WO 2007006306 | Jan 2007 | WO |
WO 2007013049 | Feb 2007 | WO |
WO 2007013064 | Feb 2007 | WO |
WO 2007015964 | Feb 2007 | WO |
WO 2007016590 | Feb 2007 | WO |
WO 2007019038 | Feb 2007 | WO |
WO 2007030598 | Mar 2007 | WO |
WO 2007030599 | Mar 2007 | WO |
WO 2007030601 | Mar 2007 | WO |
WO 2007031757 | Mar 2007 | WO |
WO 2007031762 | Mar 2007 | WO |
WO 2007031765 | Mar 2007 | WO |
WO 2007041642 | Apr 2007 | WO |
WO 2007062024 | May 2007 | WO |
WO 2007067685 | Jun 2007 | WO |
WO-2007084792 | Jul 2007 | WO |
WO 2007085396 | Aug 2007 | WO |
WO 2007087808 | Aug 2007 | WO |
WO 2007087809 | Aug 2007 | WO |
WO 2007087811 | Aug 2007 | WO |
WO 2007092397 | Aug 2007 | WO |
WO 2007095180 | Aug 2007 | WO |
WO 2007106590 | Sep 2007 | WO |
WO 2007106591 | Sep 2007 | WO |
WO 2007133618 | Nov 2007 | WO |
WO 2007143060 | Dec 2007 | WO |
WO 2008008032 | Jan 2008 | WO |
WO 2008010094 | Jan 2008 | WO |
WO 2008011774 | Jan 2008 | WO |
WO 2008012278 | Jan 2008 | WO |
WO 2008013896 | Jan 2008 | WO |
WO 2008014358 | Jan 2008 | WO |
WO 2008016304 | Feb 2008 | WO |
WO 2008027449 | Mar 2008 | WO |
WO 2008036162 | Mar 2008 | WO |
WO 2008040020 | Apr 2008 | WO |
WO 2008041926 | Apr 2008 | WO |
WO 2008043067 | Apr 2008 | WO |
WO 2008048527 | Apr 2008 | WO |
WO 2008064502 | Jun 2008 | WO |
WO 2008086397 | Jul 2008 | WO |
WO 2008100437 | Aug 2008 | WO |
WO 2008100440 | Aug 2008 | WO |
WO 2008100446 | Aug 2008 | WO |
WO 2008112304 | Sep 2008 | WO |
WO 2008131895 | Nov 2008 | WO |
WO 2008132215 | Nov 2008 | WO |
WO 2008135997 | Nov 2008 | WO |
WO 2008141470 | Nov 2008 | WO |
WO 2008154158 | Dec 2008 | WO |
WO 2009002260 | Dec 2008 | WO |
WO 2009004370 | Jan 2009 | WO |
WO 2009016603 | Feb 2009 | WO |
WO 2009016605 | Feb 2009 | WO |
WO 2009019229 | Feb 2009 | WO |
WO 2009021047 | Feb 2009 | WO |
WO 2009021353 | Feb 2009 | WO |
WO 2009034322 | Mar 2009 | WO |
WO 2009062327 | May 2009 | WO |
WO 2009066104 | May 2009 | WO |
WO 2009066106 | May 2009 | WO |
WO 2009067711 | May 2009 | WO |
WO 2009068665 | Jun 2009 | WO |
WO 2009071926 | Jun 2009 | WO |
WO 2009071929 | Jun 2009 | WO |
WO 2009071932 | Jun 2009 | WO |
WO 2009071933 | Jun 2009 | WO |
WO 2009071935 | Jun 2009 | WO |
WO 2009071948 | Jun 2009 | WO |
WO 2009078790 | Jun 2009 | WO |
WO 2009086580 | Jul 2009 | WO |
WO 2009088925 | Jul 2009 | WO |
WO 2009111655 | Sep 2009 | WO |
WO 2009114624 | Sep 2009 | WO |
WO 2009114760 | Sep 2009 | WO |
WO 2009114790 | Sep 2009 | WO |
WO 2009124473 | Oct 2009 | WO |
WO 2009124548 | Oct 2009 | WO |
WO 2009126102 | Oct 2009 | WO |
WO 2009126103 | Oct 2009 | WO |
WO 2009137194 | Nov 2009 | WO |
WO 2009140376 | Nov 2009 | WO |
WO 2009145703 | Dec 2009 | WO |
WO 2009145894 | Dec 2009 | WO |
WO 2009158125 | Dec 2009 | WO |
WO 2009158126 | Dec 2009 | WO |
WO 2009158127 | Dec 2009 | WO |
WO 2009158129 | Dec 2009 | WO |
WO-2009146441 | Dec 2009 | WO |
WO 2010014177 | Feb 2010 | WO |
WO 2010033271 | Mar 2010 | WO |
WO 2010033272 | Mar 2010 | WO |
WO 2010033769 | Mar 2010 | WO |
WO 2010035017 | Apr 2010 | WO |
WO 2010042240 | Apr 2010 | WO |
WO 2010051071 | May 2010 | WO |
WO 2010056977 | May 2010 | WO |
WO 2010059712 | May 2010 | WO |
WO 2010072395 | Jul 2010 | WO |
WO 2010078166 | Jul 2010 | WO |
WO 2010094957 | Aug 2010 | WO |
WO 2010120470 | Oct 2010 | WO |
WO 2010147533 | Dec 2010 | WO |
WO 2011049562 | Apr 2011 | WO |
WO 2011087871 | Jul 2011 | WO |
WO-2011091052 | Jul 2011 | WO |
WO 2011100851 | Aug 2011 | WO |
WO-2011091952 | Aug 2011 | WO |
WO 2011115908 | Sep 2011 | WO |
WO 2012028842 | Mar 2012 | WO |
WO 2012142002 | Oct 2012 | WO |
WO 2012174672 | Dec 2012 | WO |
WO 2013013938 | Jan 2013 | WO |
WO 2013016239 | Jan 2013 | WO |
WO 2013019438 | Feb 2013 | WO |
WO 2013043972 | Mar 2013 | WO |
WO 2013123005 | Aug 2013 | WO |
WO 2014066057 | May 2014 | WO |
WO 2014043238 | Sep 2014 | WO |
WO 2014158526 | Oct 2014 | WO |
Entry |
---|
US 7,186,244 B1, 03/2007, Hunt et al. (withdrawn) |
Fleischmann, W. et al., “Vacuum Sealing: Indication, Technique, and Results”, Eur J Orthop Surg Traumatol, vol. 5, 1995, pp. 37-40, in 5 pages. |
Greer, S. et al., “Techniques for Applying Subatmospheric Pressure Dressing to Wounds in Difficult Regions of Anatomy”, JWOCN, vol. 26(5), 1999, pp. 250-253, in 4 pages. |
International Report on Patentability, re PCT Application No. PCT/US2011/041521, dated Jun. 25, 2013. |
International Search Report and Written Opinion, re PCT Application No. PCT/US2011/041521, dated Oct. 7, 2011. |
Jeter, K. et al., “Managing Draining Wounds and Fistulae: New and Established Methods”, Chronic Wound Care, 1990, pp. 240-246, in 7 pages. |
KCI V.A.C. Granufoam Bridge Dressing Product Brochure (2009), in 2 pages. |
Bevan D., et al., “Diverse and potent activities of HGF/SF in skin wound repair,” Journal of Pathology, vol. 203, 2004, pp. 831-838. |
Info V.A.C. User Manual, KCI on Dec. 1, 2006 in 76 pages. |
Landis E.M., et al., “The Effects of Alternate Suction and Pressure on Blood Flow to the Lower Extremities,” Alternate Suction and Pressure, J Clin Invest, Sep. 1993, vol. 12 (5), pp. 925-961. |
Mitchell R.N., et al., “Role of Stem Cells in Tissue Homeostasis,” Pocket Companion to Robbins and Cotran Pathologic Basis of Disease, 7th Edition, 2006, p. 55 (3 pages). |
Morykwas M.J., et al., “Nonsurgical Modalities to Enhance Healing and Care of Soft Tissue Wounds,” Journal of the Southern Orthopaedic Association, vol. 6, No. 4, 1997, pp. 279-288. |
Number | Date | Country | |
---|---|---|---|
20180304065 A1 | Oct 2018 | US |
Number | Date | Country | |
---|---|---|---|
61426432 | Dec 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14730040 | Jun 2015 | US |
Child | 15952070 | US | |
Parent | 13381884 | US | |
Child | 14730040 | US |